Study: Psilocybin enhances therapy in patients with major depression
The Brown University Psychopharmacology Update – January 07, 2021
Source: OpenAlex
Summary
Patients with major depressive disorder experienced rapid, lasting symptom improvement after receiving the hallucinogen psilocybin alongside psychotherapy. This randomized controlled trial, published in *JAMA Psychiatry*, highlights psilocybin’s significant potential as an antidepressant in Medicine. Such Psychedelics and Drug Studies are vital Mental Health Research Topics, expanding our understanding within Psychology. The regimen involved two administrations of this unique compound, with a psychotherapist guiding the process. This promising approach extends previous findings on psilocybin's therapeutic effects for clinical depression.
Abstract
Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open‐label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with cancer and treatment‐resistant depression, the researchers stated. Study results were published online Nov. 4, 2020, in JAMA Psychiatry .